乳糜泻治疗市场机会、成长动力、产业趋势分析及 2025-2034 年预测

2024 年全球乳糜泻治疗市场价值为 6.499 亿美元，预计 2025 年至 2034 年的复合年增长率为 10.6%。乳糜泻盛行率的不断上升以及医疗保健专业人员对先进诊断工具的认识不断提高，正在推动市场的发展。随着检测方法的改进，越来越多的人被诊断出患有癌症，对有效治疗的需求不断上升。研发的进步正在加速药物治疗的引入，进一步推动市场扩张。乳糜泻患者以外的人群对无麸质饮食的偏好激增，以及创新非侵入性诊断工具的采用，正在加强该行业的发展。 HLA 分型和抗体检测技术的进步正在提高诊断准确性并缩短检测时间，从而提高诊断率并增加对治疗方案的需求。

该市场专注于乳糜泻的管理和治疗，乳糜泻是一种由遗传易感人群摄取麸质引发的自体免疫疾病。它包括旨在缓解症状、预防併发症和增强患者健康的药物、补充剂和疗法。市场分为无麸质饮食、维生素和矿物质补充剂以及医疗疗法。维生素和矿物质补充剂类别占主导地位，2024 年贡献 3.151 亿美元，因为乳糜泻会损害营养吸收，需要补充剂来维持健康。特别强调钙和维生素 D 的摄入，以解决与吸收不良相关的骨骼健康问题。

消费者越来越寻求支持肠道健康的专门补充剂，从而推动了市场扩张。根据给药途径，市场分为口服治疗和肠外治疗。口服药物市场在 2024 年占据了 63.4% 的显着份额，因其便利性而受到青睐，患者无需医疗保健提供者的帮助即可管理自己的病情。新型口服製剂（包括酵素补充剂和免疫调节剂）的引入正在拓宽治疗选择并提高患者的依从性。这些进步提高了药物的功效、生物利用度和吸收率，提高了采用率。与注射和输液相比，口服疗法由于给药方便而仍然受到青睐，适合需要灵活治疗方案的忙碌生活患者。

最终用户市场分为医院、专科诊所、家庭护理机构和其他类别。医院在 2024 年占最大的份额，预计到 2034 年将达到 9.041 亿美元。治疗性疫苗和抗发炎药物的整合正在扩大医院的治疗服务。先进的诊断工具和多种治疗选择可以改善患者的治疗效果，增加因疾病管理而入院的人数。医院提供必要的一线治疗，包括营养疗法、无麸质饮食和生物製剂，而这些在初级保健环境中并不总是可用的。对生物製剂和酵素疗法的依赖推动了频繁的医院就诊，从而促进了市场成长。

2024年，美国以2.603亿美元的估值占据北美市场的主导地位。乳糜泻病例的增加加剧了对先进治疗的需求。美国占北美病例的很大一部分，凸显了患者群体的不断扩大。主要市场参与者对创新治疗方法、增强诊断系统和策略差异化的持续研究正在促进产业成长。药物进步旨在减轻免疫系统反应，解决最紧迫的未满足医疗需求之一。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 乳糜泻盛行率上升
    • 治疗方案的技术进步
    • 无麸质产品需求不断成长
    • 乳糜泻诊断技术日益进步
  • 产业陷阱与挑战
    • 无麸质产品成本高
    • 严格的监管审批
• 成长潜力分析
• 监管格局
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：依治疗方式，2021 年至 2034 年

• 主要趋势
• 维生素和矿物质补充剂
• 无麸质饮食
• 医学疗法

第六章：市场估计与预测：依管理路线，2021 年至 2034 年

• 主要趋势
• 口服
• 肠外

第七章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 医院
• 专科诊所
• 居家照护环境
• 其他最终用途

第八章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• ActoBio
• Amgen
• Amneal Pharmaceuticals
• BioLineRx
• Calypso Biotech
• General Mills
• Glenmark Life Sciences
• Hikma Pharmaceuticals
• Innovate Biopharmaceutical
• Novartis
• Takeda Pharmaceutical Company
• Teva Pharmaceutical
• Viatris
• Zydus Pharmaceuticals

The Global Celiac Disease Treatment Market was valued at USD 649.9 million in 2024 and is projected to expand at a CAGR of 10.6% from 2025 to 2034. The increasing prevalence of celiac disease and growing awareness among healthcare professionals regarding advanced diagnostic tools are driving the market. As more people are diagnosed due to improved detection methods, the demand for effective treatment continues to rise. Advancements in research and development are accelerating the introduction of pharmaceutical treatments, further propelling market expansion. The surge in gluten-free dietary preferences beyond the celiac population and the adoption of innovative non-invasive diagnostic tools are strengthening the industry. Technological advancements in HLA typing and antibody testing are enhancing diagnostic accuracy and reducing test duration, thereby increasing diagnosis rates and boosting demand for therapeutic solutions.

The market focuses on the management and treatment of celiac disease, an autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals. It includes pharmaceutical products, supplements, and therapies designed to alleviate symptoms, prevent complications, and enhance patient well-being. The market is segmented into gluten-free diets, vitamin and mineral supplements, and medical therapies. The vitamins and minerals supplements category dominated, contributing USD 315.1 million in 2024, as celiac disease impairs nutrient absorption, necessitating supplementation to maintain health. Calcium and vitamin D intake is particularly emphasized for addressing bone health concerns associated with malabsorption.

Consumers are increasingly seeking specialized supplements that support gut health, fueling market expansion. Based on administration routes, the market is divided into oral and parenteral treatments. The oral segment held a significant share of 63.4% in 2024, favored for its convenience, allowing patients to manage their condition without healthcare provider assistance. The introduction of novel oral formulations, including enzyme supplements and immune modulators, is broadening treatment options and improving patient adherence. These advancements enhance drug efficacy, bioavailability, and absorption, increasing adoption rates. Oral therapies remain preferred due to their ease of administration compared to injections and infusions, accommodating patients with busy lifestyles who require flexible treatment solutions.

The end-user market is classified into hospitals, specialty clinics, homecare settings, and other categories. Hospitals accounted for the largest segment in 2024, with projections reaching USD 904.1 million by 2034. The integration of therapeutic vaccines and anti-inflammatory drugs is expanding hospital-based treatment offerings. Advanced diagnostic tools and a diverse range of therapeutic options improve patient outcomes, increasing hospital admissions for disease management. Hospitals provide essential first-line treatments, including nutrition therapy, gluten-free diets, and biologics, which are not always available in primary care settings. The reliance on biologic agents and enzyme therapies drives frequent hospital visits, contributing to market growth.

In 2024, the United States dominated the North American market with a valuation of USD 260.3 million. Rising celiac disease cases are intensifying the demand for advanced treatments. The U.S. accounts for a significant portion of North American cases, highlighting an expanding patient base. Ongoing research into innovative treatment approaches, enhanced diagnostic systems, and strategic differentiation by key market players is fostering industry growth. Pharmaceutical advancements aim to mitigate immune system reactions, addressing one of the most pressing unmet medical needs.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of celiac disease
    • 3.2.1.2 Technological advancements in therapeutic options
    • 3.2.1.3 Increasing demand for gluten-free products
    • 3.2.1.4 Increasing diagnostic technologies for celiac disease diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of gluten-free products
    • 3.2.2.2 Stringent regulatory approvals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter’s analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Vitamins and mineral supplements
• 5.3 Gluten-free diet
• 5.4 Medical therapies

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Homecare settings
• 7.5 Other End Use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 ActoBio
• 9.2 Amgen
• 9.3 Amneal Pharmaceuticals
• 9.4 BioLineRx
• 9.5 Calypso Biotech
• 9.6 General Mills
• 9.7 Glenmark Life Sciences
• 9.8 Hikma Pharmaceuticals
• 9.9 Innovate Biopharmaceutical
• 9.10 Novartis
• 9.11 Takeda Pharmaceutical Company
• 9.12 Teva Pharmaceutical
• 9.13 Viatris
• 9.14 Zydus Pharmaceuticals